内科

目的观察丁苯酞注射液联合高压氧治疗进展性脑梗死患者的临床效果。方法选取2019年8月至2020年11月我院收治的进展性脑梗死患者112例为研究对象，随机分为观察组与对照组，每组56例。对照组患者在常规治疗的基础上给予丁苯酞治疗，观察组患者在对照组患者的基础上再给予高压氧治疗。评估比较两组患者治疗前后的美国国立卫生研究院卒中量表（NIHSS）评分，比较两组患者的临床疗效；检测比较两组患者治疗前后的血清C反应蛋白(CRP)、D-二聚体(D-D)水平。结果治疗前，两组患者NIHSS评分比较，差异无统计学意义（P＞0.05）；治疗24 d后，两组患者的NIHSS评分均显著降低，观察组患者的评分显著低于对照组，差异有统计学意义(P＜0.05)；观察组患者的治疗总有效率（87.50%）显著高于对照组（71.42%），差异有统计学意义（P＜0.05）。治疗前，两组患者的血清CRP、D-D水平比较，差异无统计学意义（P＞0.05）；治疗24 d后，两组患者的CRP、D-D水平均明显降低，观察组患者的水平显著低于对照组，差异有统计学意义（P＜0.05）。结论丁苯酞注射液联合高压氧治疗进展性脑梗死患者可发挥协同增效作用，显著降低血清CRP及D-D水平，有效促进患者神经功能缺损的恢复，提高临床治疗效果，改善患者预后。

ObjectiveTo observe the clinical efficacy of butylphthalide injection combined with hyperbaric oxygen in the treatment of patients with progressive cerebral infarction. Methods112 patients with progressive cerebral infarction treated in our hospital from August 2019 to November 2020 were enrolled as the research objects, and they were randomly divided into observation group and control group, with 56 cases in each group. The control group was treated with butylphthalide based on the conventional treatment, while the observation group was given hyperbaric oxygen treatment on the basis of the control group. The national institute of health stroke scale (NIHSS) scores of the two groups before and after treatment were evaluated and compared, and the clinical efficacy of the two groups were compared. The levels of serum C-reactive protein (CRP) and D-dimer (D-D) were detected and compared between the two groups before and after treatment. ResultsBefore treatment, there was no statistically significant difference in NIHSS score between the two groups (P＞0.05). After 24 days of treatment, the NIHSS scores of the two groups decreased significantly, and the score of the observation group were significantly lower than that of the control group, with a statistically significant difference (P＜0.05). The total effective rate of the observation group (87.50%) was significantly higher than that of the control group (71.42%), with a statistically significant difference (P＜0.05). Before treatment, there were no statistically significant differences in serum CRP, D-D levels between the two groups (P＞0.05). After 24 days of treatment, the levels of CRP and D-D significantly decreased in both groups, while the levels of the observation group were significantly lower than those of the control group, with statistically significant differences (P＜0.05). ConclusionButylphthalide injection combined with hyperbaric oxygen in the treatment of patients with progressive cerebral infarction can play a synergistic role, significantly reduce serum CRP and D-D levels, effectively promote the recovery of neurological deficits, improve the clinical therapeutic effect and the prognosis of patients.